SCHEDULE: ArrowMark Discloses 3.67% Stake in PMV Pharmaceuticals

ArrowMark Colorado Holdings, LLC has reported beneficial ownership of 1,959,579 shares, representing 3.67% of the outstanding common stock of PMV Pharmaceuticals, Inc., as of June 30, 2026.

Summary

• ArrowMark Colorado Holdings, LLC has filed a Schedule 13G, indicating it is an "IA" (Investment Adviser) type of reporting person.
• The filing discloses beneficial ownership of 1,959,579 shares of common stock in PMV Pharmaceuticals, Inc.
• This ownership stake represents 3.67% of the class of securities.
• ArrowMark Colorado Holdings, LLC has sole voting power and sole dispositive power over these shares.
• The filing is an amendment (Amendment No. 3) to a previous filing, with the event date requiring this statement being June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it indicates institutional interest but provides no operational or financial performance data for PMV Pharmaceuticals.

Positives

• ArrowMark Colorado Holdings, LLC, an investment adviser, has taken a significant stake in PMV Pharmaceuticals, Inc., potentially signaling confidence in the company's future prospects.
• The reporting person holds sole voting and dispositive power, indicating clear control over their investment decisions regarding PMV Pharmaceuticals.

Risks

• As a Schedule 13G filer, ArrowMark is generally considered a passive investor, but any shift in their investment strategy could impact PMV Pharmaceuticals' stock price.
• The filing does not provide specific reasons for the acquisition or any forward-looking statements from ArrowMark regarding their intentions with PMV Pharmaceuticals.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from PMV Pharmaceuticals. It solely reports the ownership stake of ArrowMark Colorado Holdings, LLC.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by investment advisers often indicate a growing institutional interest in a company, which can be a positive signal for other investors. However, the specific sector of PMV Pharmaceuticals is not detailed in this filing, limiting broader industry context.

Stakeholder Impact

• Shareholders: The increased institutional interest may be viewed positively, potentially influencing share price and liquidity.
• Management of PMV Pharmaceuticals: May need to engage with ArrowMark Colorado Holdings, LLC regarding their investment strategy.
• Potential Investors: The filing provides information about a significant shareholder, which can be a factor in investment decisions.

Next Steps

• ArrowMark Colorado Holdings, LLC will continue to hold its shares in PMV Pharmaceuticals, Inc.
• Further filings may be required if ArrowMark's ownership stake changes significantly.

Key Dates

Keywords

Schedule 13G, ArrowMark Colorado Holdings, LLC, PMV Pharmaceuticals, Inc., Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Shareholder